Russian Prime Minister Mikhail Mishustin has signed a document designating medical institutions authorized to produce and utilize biotechnological medicinal products (BTMPs). These are personalized drugs developed based on the unique genetic characteristics of each patient, representing a modern approach in gene and cell therapy.
The official registry includes 18 leading medical organizations from various regions of the country, including Moscow, St. Petersburg, the Kaluga, Novosibirsk, Tomsk, and Irkutsk regions, as well as the Primorsky Krai and the Republic of Tatarstan:
- Federal Scientific and Clinical Center for Physical and Chemical Medicine named after Yu.M. Lopukhin (Moscow)
- Federal Brain and Neurotechnology Center (Moscow)
- N.N. Blokhin National Medical Research Center of Oncology (Moscow)
- M.P. Chumakov Federal Scientific Center for the Study and Development of Immunobiological Products (Moscow)
- V.A. Nasonova Research Institute of Rheumatology (Moscow)
- B.V. Petrovsky National Research Center for Surgery (Moscow)
- Federal Scientific and Clinical Center for Intensive Care and Rehabilitation (Moscow)
- D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductive Medicine (St. Petersburg)
- Institute of Experimental Medicine (St. Petersburg)
- National Medical Research Center of Radiology (Kaluga Region)
- Research Institute of Fundamental and Clinical Immunology (Novosibirsk Region)
- Federal Research Center for Fundamental and Translational Medicine (Novosibirsk Region)
- Institute of Cytology and Genetics (Novosibirsk Region)
- Tomsk National Research Medical Center (Tomsk Region)
- Far Eastern Federal University (Primorsky Krai)
- Kazan (Volga Region) Federal University (Republic of Tatarstan)
- Research Institute of Complex Issues of Cardiovascular Diseases (Kemerovo Region)
- Irkutsk Research Center for Surgery and Traumatology (Irkutsk Region)
Earlier, it was reported that Russia plans to establish a federal biotechnological center to ensure the country’s pharmaceutical security. This center will be located in the Republic of Mordovia.
Source: GxP News, December 17, 2024.
